| Literature DB >> 27694956 |
Yi-Fang Li1,2, Yi-Qun Chang1, Jie Deng1,2, Wei-Xi Li2,3, Jie Jian1, Jia-Suo Gao1, Xin Wan1,2, Hao Gao1, Hiroshi Kurihara1,2, Ping-Hua Sun1, Rong-Rong He1,2.
Abstract
The extraordinary hypolipidemic effects of polyphenolic compounds from tea have been confirmed in our previous study. To gain compounds with more potent activities, using the conformations of the most active compound revealed by molecular docking, a 3D-QSAR pancreatic lipase inhibitor model with good predictive ability was established and validated by CoMFA and CoMISA methods. With good statistical significance in CoMFA (r2cv = 0.622, r2 = 0.956, F = 261.463, SEE = 0.096) and CoMISA (r2cv = 0.631, r2 = 0.932, F = 75.408, SEE = 0.212) model, we summarized the structure-activity relationship between polyphenolic compounds and pancreatic lipase inhibitory activities and find the bulky substituents in R2, R4 and R5, hydrophilic substituents in R1 and electron withdrawing groups in R2 are the key factors to enhance the lipase inhibitory activities. Under the guidance of the 3D-QSAR results, (2R,3R,2'R,3'R)-desgalloyloolongtheanin-3,3'-O-digallate (DOTD), a potent lipase inhibitor with an IC50 of 0.08 μg/ml, was obtained from EGCG oxidative polymerization catalyzed by crude polyphenol oxidase. Furthermore, DOTD was found to inhibit lipid absorption in olive oil-loaded rats, which was related with inhibiting the activities of lipase in the intestinal mucosa and contents.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27694956 PMCID: PMC5046073 DOI: 10.1038/srep34387
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Molecular alignment based on docking results.
(a) Conformation of compound 8 retrieved from docking result; (b) Alignment of the training compounds; (c) The binding mode between selected compound 8.
Comparison of actual and predicted biological activity in terms of pIC50 of the compounds by using CoMSIA and CoMFA models.
| Compound | Actual | CoMFA | CoMSIA | ||
|---|---|---|---|---|---|
| Pred. | Res | Pred. | Res | ||
| 1 | 6.8861 | 6.758 | −0.1281 | 6.899 | 0.141 |
| 2 | 6.6778 | 6.752 | 0.0742 | 6.64 | −0.112 |
| 3 | 4.5229 | 4.821 | 0.2981 | 4.749 | −0.072 |
| 4 | 6.4685 | 6.201 | −0.2675 | 6.153 | −0.048 |
| 5 | 4.5229 | 4.891 | 0.3681 | 4.921 | 0.03 |
| 6 | 6.2441 | 6.123 | −0.1211 | 6.411 | 0.288 |
| 7 | 6.4089 | 6.335 | −0.0739 | 6.33 | −0.005 |
| 8 | 6.9586 | 6.771 | −0.1876 | 7.003 | 0.232 |
| 9 | 6.1308 | 6.237 | 0.1062 | 5.89 | −0.347 |
| 10 | 6.0132 | 6.062 | 0.0488 | 5.964 | −0.098 |
| 11* | 6.7959 | 6.211 | −0.5849 | 6.312 | 0.101 |
| 12 | 5.9101 | 5.578 | −0.3321 | 5.563 | −0.015 |
| 13 | 6.0315 | 6.732 | 0.7005 | 6.542 | −0.19 |
| 14 | 6.1612 | 6.09 | −0.0712 | 6.002 | −0.088 |
| 15 | 5.5513 | 6.085 | 0.5337 | 6.001 | −0.084 |
| 16 | 5.0605 | 5.225 | 0.1645 | 5.093 | −0.132 |
| 17 | 6.7212 | 6.544 | −0.1772 | 6.523 | −0.021 |
| 18 | 5.4841 | 5.154 | −0.3301 | 5.341 | 0.187 |
| 19 | 6.6021 | 6.66 | 0.0579 | 6.614 | −0.046 |
| 20 | 6.9586 | 7.05 | 0.0914 | 7.059 | 0.009 |
| 21 | 6.5229 | 6.456 | −0.0669 | 6.816 | 0.36 |
| 22 | 5.6402 | 5.597 | −0.0432 | 5.674 | 0.077 |
| 23 | 5.058 | 5.066 | 0.008 | 5.122 | 0.056 |
| 24 | 5.4841 | 5.19 | −0.2941 | 5.295 | 0.105 |
| 25 | 4.7622 | 5.112 | 0.3498 | 5.178 | 0.066 |
| 26 | 6.7447 | 6.765 | 0.0203 | 6.944 | 0.179 |
| 27 | 5.4895 | 5.126 | −0.3635 | 5.272 | 0.146 |
| 28 | 5.6655 | 5.579 | −0.0865 | 5.481 | −0.098 |
| 29 | 7 | 6.983 | −0.017 | 6.971 | −0.012 |
| 30 | 5.1643 | 5.196 | 0.0317 | 5.171 | −0.025 |
| 31 | 6.6021 | 6.977 | 0.3749 | 6.959 | −0.018 |
| 32 | 6.2147 | 6.396 | 0.1813 | 6.076 | −0.32 |
| 33 | 6.8861 | 6.805 | −0.0811 | 6.934 | 0.129 |
| 34 | 7 | 6.861 | −0.139 | 7.047 | 0.186 |
| 35 | 6.8239 | 6.768 | −0.0559 | 6.802 | 0.034 |
| 36 | 6.5229 | 6.599 | 0.0761 | 6.565 | −0.034 |
| 37 | 4.7857 | 5.214 | 0.4283 | 5.204 | −0.01 |
*Test set.
Figure 2CoMFA and CoMSIA graphs of actual and predicted pIC50 values.
(a) CoMFA; (b) CoMSIA.
PLS statistics of the CoMFA and CoMISA 3D-QSAR models.
| PLS | CoMFA | CoMSIA |
|---|---|---|
| 0.622 | 0.631 | |
| 0.956 | 0.932 | |
| ONC | 3 | 4 |
| SEE | 0.069 | 0.122 |
| F values | 261.463 | 75.408 |
| Steric | 0.446 | 0.232 |
| Electrostatic | 0.554 | |
| Hydrophobic | 0.345 | |
| H-bond donor | 0.423 | |
| 0.918 | 0.773 |
q2: Cross-validated correlation coefficient. r2: Non-cross-validated coefficient. ONC: Optimal number of components. SEE: Standard error of estimate. F: F-test value. r2pred: Predictive correlation coefficient.
Figure 3Contours of CoMFA and CoMSIA analysis with compound 8 as template molecule.
(a) The steric fields of CoMFA. Green contours refer to the regions in which bulky groups elevate activities. Yellow contours suggest the regions in which bulky groups reduce activities; (b) The electrostatic fields of CoMFA. The contours in blue and red respectively represent favored regions of electron-donating groups and electron-withdrawing groups; (c) The contours in green and yellow respectively indicate bulky and minor groups favored regions; (d) Hydrophobic fields of CoMSIA. The contours in blue and red respectively locate the favored hydrophilic and hydrophobic regions; (e) Hydrogen-bond donor fields of CoMSIA. The contours in cyan and purple respectively locate the regions in which hydrogen-bond donor groups are favorable and unfavorable.
Figure 4Synthesis guided by SAR.
(a) The Structure-activity relationship analyzed by 3D-QSAR and docking; (b) The Structure of DOTD.
Figure 5In vivo activity of DOTD.
(a) Effects of DOTD on TG levels in the plasma of rats loaded with olive oil; (b) Effects of DOTD on lipase activity in the mucosa and the contents of small intestine of rats loaded with olive oil. Values are expressed as mean ± S.D. (n = 7 in each group). *P < 0.05, **P < 0.01 vs. control group, and †P < 0.05, ††P < 0.01 vs. EGCG group.
Figure 6Head-to-head and head-to-tail polymerization.
The training and test set compounds.
The basic skeletons of these compounds are shown in Fig. 7.
Inhibitory Activities of Tea Polyphenols on Pancreatic Lipase.
| No | Compoud Name | IC50(μM) | pIC50 |
|---|---|---|---|
| 1 | assamicain A | 0.13 | 6.8861 |
| 2 | assamicain B | 0.21 | 6.6778 |
| 3 | (−)-epicatechin (EC) | >30 | 4.5229 |
| 4 | (−)-epicatechin-3-O-gallate (ECG) | 0.34 | 6.4685 |
| 5 | (−)-epigallocatechin (EGC) | >30 | 4.5229 |
| 6 | (−)-gallocatechin-3-O-gallate (GCG) | 0.57 | 6.2441 |
| 7 | (−)-epigallocatechin-3-O-gallate (EGCG) | 0.39 | 6.4089 |
| 8 | (−)-epigallocatechin-3,5-di-O-gallate | 0.11 | 6.9586 |
| 9 | (−)-epicatechin 3-O-(3′-O-methyl)-gallat | 0.74 | 6.1308 |
| 10 | (−)-epigallocatechin-3-O-p-coumaroate | 0.97 | 6.0132 |
| 11 | (−)-epicatechin(4β-8)-(−)-epigallocatechin 3-O-gallate | 0.16 | 6.7959 |
| 12 | (−)-epigallocatechin (4β-8)-(−)-epicatechin-3-O-gallate | 1.23 | 5.9101 |
| 13 | (−)-epicatechin-3-O-gallate-(4β-8)-(−)-epigallocatechin3-O-gallate | 0.93 | 6.0315 |
| 14 | (−)-epigallocatechin-3-O-gallate-(4β-8)-(−)-epicatechin 3-O-gallate | 0.69 | 6.1612 |
| 15 | (−)-epiafzelechin 3-O-gallate | 2.81 | 5.5513 |
| 16 | (+)-catechin (4α-8) (−)-epigallocatechin | 8.7 | 5.0605 |
| 17 | (+)-catechin (4α-8) (−)-epigallocatechin 3-O-gallate | 0.19 | 6.7212 |
| 18 | (+)-gallocatechin (4α-8) (−)-epicatechin | 3.28 | 5.4841 |
| 19 | Oolongtheanin | 0.25 | 6.6021 |
| 20 | oolonghomobisflavan A | 0.11 | 6.9586 |
| 21 | mono-desgalloyl oolonghomobisflavan A | 0.3 | 6.5229 |
| 22 | di-desgalloyl oolonghomobisflavan B | 2.29 | 5.6402 |
| 23 | procyanidin B2 | 8.75 | 5.0580 |
| 24 | procyanidin B3 | 3.28 | 5.4841 |
| 25 | procyanidin B4 | 17.29 | 4.7622 |
| 26 | prodelphinidin A2-3′-O-gallate | 0.18 | 6.7447 |
| 27 | prodelphinidin B2 | 3.24 | 5.4895 |
| 28 | prodelphinidin B2- 3′-O-gallate | 2.16 | 5.6655 |
| 29 | prodelphinidin B2-3,3′-di-O-gallate | 0.1 | 7.0000 |
| 30 | prodelphinidin B4 | 6.85 | 5.1643 |
| 31 | prodelphinidin B4-3-O-gallate | 0.25 | 6.6021 |
| 32 | prodelphinidin B5-3,3′-di-O-gallate | 0.61 | 6.2147 |
| 33 | theaflavin-3′-O-gallate | 0.13 | 6.8861 |
| 34 | theaflavin-3,3′-di-O-gallate | 0.1 | 7.0000 |
| 35 | theasinensin A | 0.15 | 6.8239 |
| 36 | theasinensin B | 0.3 | 6.5229 |
| 37 | theasinensin C | 16.38 | 4.7857 |
Figure 7The basic skeletons of the training and test set compounds in Table 3
. Each structure represents the skeleton of the corresponding molecules in Table 3.